Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
This page provides a historical news archive for Cerevel Therapeutics Holdings, Inc. (formerly Nasdaq: CERE), a neuroscience-focused biopharmaceutical company that became part of AbbVie following the completion of an acquisition announced by AbbVie on August 1, 2024. Before the transaction, Cerevel regularly issued updates on its clinical pipeline, corporate strategy and capital raising activities.
News items for Cerevel include detailed announcements on its key investigational therapies such as emraclidine, tavapadon, darigabat, CVL-871 and CVL-354. These releases cover topics like Phase 2 and Phase 3 trial designs, topline clinical results, regulatory designations and development plans in schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, Parkinson’s disease, mood disorders and related neuroscience indications. For example, Cerevel announced positive topline results from the pivotal Phase 3 TEMPO-3 adjunctive trial of tavapadon in people living with Parkinson’s disease.
Investors and researchers can also review historical corporate and financial communications, including quarterly financial results, business updates, investor webcasts, and the October 2023 public offering of common stock that Cerevel stated would support operations and planned data readouts. In addition, the archive reflects transaction-related news, such as the December 6, 2023 joint announcement by AbbVie and Cerevel of a definitive acquisition agreement, and subsequent commentary from law firms examining the terms of the merger.
Although CERE shares are no longer expected to trade following the closing of the AbbVie acquisition, this news history remains useful for understanding how Cerevel’s neuroscience programs evolved, how management communicated clinical milestones, and how the acquisition rationale was framed by AbbVie. Users interested in ongoing development of these assets should consult AbbVie’s current disclosures, while using this page as a record of Cerevel’s standalone public-company era.
Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Dr. Raymond Sanchez to its Board of Directors effective August 12, 2025.
Dr. Sanchez brings over 20 years of strategic experience in life sciences and currently serves as Senior Advisor at Bain Capital Life Sciences. His extensive background includes roles as Chief Medical Officer at Cerevel Therapeutics and senior positions at Otsuka Pharmaceutical. The appointment comes as Alto prepares to initiate its potentially pivotal Phase 2b trial of ALTO-207.
A psychiatrist by training and former Chief Resident at Yale School of Medicine, Dr. Sanchez's expertise in CNS drug development aligns with Alto's mission to revolutionize neuropsychiatric treatment through precision medicine approaches.
AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.
The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.
BFA LLP has announced an investigation into the merger between Cerevel Therapeutics (NASDAQ: CERE) and AbbVie. Under the merger terms, AbbVie will buy all outstanding shares of Cerevel for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This transaction, approved by the boards of directors of both companies, is set to close in mid-2024. BFA LLP suspects that Cerevel's board was conflicted and agreed to an unfair price for shareholders. Shareholders may have legal options and can obtain more information or legal representation on a contingency fee basis by visiting BFA's website or contacting them directly.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Cerevel Therapeutics Hldng (CERE)?
What is the market cap of Cerevel Therapeutics Hldng (CERE)?
